Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 5:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 337 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: The Methodist Hospital Research Institute Clear all
Completed Not applicable Interventional Results available

Opioid Use After Thyroid and Parathyroid Surgeries

NCT04955444
View directory record Official record
Conditions
Thyroidectomy, Parathyroidectomy, Opioid Use, Pain, Postoperative
Interventions
Quality improvement bundle
Other
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Oct 11, 2026, 5:55 AM EDT
Terminated Phase 4 Interventional

Adrenal Insufficiency in Septic Shock

NCT00842933
View directory record Official record
Conditions
Septic Shock, Acute Adrenal Insufficiency
Interventions
Corticosteroid
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2011 · Synced Oct 11, 2026, 5:55 AM EDT
Completed Phase 1 Interventional

Allogeneic Neuroblastoma Cells for Relapsed/ Refractory Neuroblastoma, CYCHEALL

NCT01713439
View directory record Official record
Conditions
Neuroblastoma
Interventions
Injection of allogeneic neuroblastoma cells
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 21 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2016
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 12, 2023 · Synced Oct 11, 2026, 5:55 AM EDT
Enrolling by invitation Phase 2 Interventional

Belumosudil for Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation

NCT06751602
View directory record Official record
Conditions
Rejection Chronic Renal
Interventions
Belumosudil 200 mg QD, Placebo
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 11, 2026, 5:55 AM EDT
Not listed Phase 2 Interventional

Systemic and Central Inflammation in AD

NCT06384378
View directory record Official record
Conditions
Alzheimer Disease
Interventions
11C-ER176
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
50 Years to 86 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Oct 11, 2026, 5:55 AM EDT
Active, not recruiting Phase 1 Interventional

Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer

NCT03742245
View directory record Official record
Conditions
Breast Cancer Metastatic, Breast Cancer
Interventions
Olaparib, Vorinostat
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 11, 2026, 5:55 AM EDT
Withdrawn Phase 1 Interventional

Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positive Lymphomas and Solid Malignancies

NCT02780011
View directory record Official record
Conditions
CD30-positive Lymphoma, CD30-positive Solid Tumor
Interventions
Brentuximab Vedotin, Alsertib
Drug
Lead sponsor
Eric Bernicker, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 27, 2018 · Synced Oct 11, 2026, 5:55 AM EDT
Completed Phase 1 Interventional

CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM

NCT01109095
View directory record Official record
Conditions
Glioblastoma Multiforme (GBM)
Interventions
HER.CAR CMV-specific CTLs
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 25, 2019 · Synced Oct 11, 2026, 5:55 AM EDT
Completed No phase listed Observational Results available

Evaluation of Contrast-Enhanced Ultrasound to Detect Endoleaks After Endovascular Aortic Aneurysm Repair

NCT01005212
View directory record Official record
Conditions
Endoleaks
Interventions
Definity
Drug
Lead sponsor
E. Peden, MD
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 12, 2024 · Synced Oct 11, 2026, 5:55 AM EDT
Terminated Not applicable Interventional

Knee Isometric Program (KIP) Home Exercise Programs (HEP) Physical Therapy (PT) Study

NCT06536426
View directory record Official record
Conditions
Anterior Knee Pain Syndrome
Interventions
Knee Isometric Program (KIP)
Behavioral
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 11, 2026, 5:55 AM EDT
Withdrawn Phase 1 Interventional

Safety of Autologous Human Umbilical Cord Blood Mononuclear Fraction to Treat Acquired Hearing Loss in Children

NCT01343394
View directory record Official record
Conditions
Hearing Loss
Interventions
Autologous Human Umbilical Cord Blood
Biological
Lead sponsor
Aryn Knight
Other
Eligibility
6 Weeks to 18 Months
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Oct 11, 2026, 5:55 AM EDT
Active, not recruiting Phase 1 Interventional

T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With HER2-Positive CNS Tumors

NCT02442297
View directory record Official record
Conditions
Brain Tumor, Recurrent, Brain Tumor, Refractory
Interventions
HER2-specific T cells
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
3 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2037
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 11, 2026, 5:55 AM EDT
Completed Phase 1 Interventional

Her2 and TGFBeta Cytotoxic T Cells in Treatment of Her2 Positive Malignancy

NCT00889954
View directory record Official record
Conditions
HER2 Positive Malignancies
Interventions
TGFBeta resistant HER2/EBV-CTLs
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
3 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2018 · Synced Oct 11, 2026, 5:55 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer

NCT03820141
View directory record Official record
Conditions
Breast Cancer
Interventions
Durvalumab, Trastuzumab, Pertuzumab
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 11, 2026, 5:55 AM EDT
Not listed Not applicable Interventional

Neurostimulation of Spinal Nerves That Affect the Heart

NCT01124136
View directory record Official record
Conditions
Chronic Heart Failure
Interventions
Neurostimulation + Medication Management (Standard of Care), Standard of Care (Control)
Device · Drug
Lead sponsor
Jerry Estep, MD
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 12, 2018 · Synced Oct 11, 2026, 5:55 AM EDT
Active, not recruiting Not applicable Interventional

The Minimally Invasive Coronary Surgery Compared to STernotomy Coronary Artery Bypass Grafting Trial

NCT03447938
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
MICS CABG, Conventional CABG
Procedure
Lead sponsor
Ottawa Heart Institute Research Corporation
Other
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • La Crosse, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 11, 2026, 5:55 AM EDT
Not listed No phase listed Observational

Prospective Cohort of Transitional Urology Patients

NCT03061084
View directory record Official record
Conditions
Spina Bifida, Myelomeningocele, Meningocele, Bladder Exstrophy, Genitourinary Congenital Anomalies, Cloacal Exstrophy
Interventions
Not listed
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 6, 2023 · Synced Oct 11, 2026, 5:55 AM EDT
Completed Phase 1Phase 2 Interventional

Personalized Antisense Oligonucleotide Therapy for A Single Participant With TARDBP ALS

NCT07095712
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
nL-TARD-001
Drug
Lead sponsor
n-Lorem Foundation
Other
Eligibility
49 Years to 49 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 11, 2026, 5:55 AM EDT
Recruiting No phase listed Observational

Estab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1)

NCT03981575
View directory record Official record
Conditions
Myotonic Dystrophy 1, DM1
Interventions
Not listed
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 70 Years
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
10
States / cities
La Jolla, California • Los Angeles, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 11, 2026, 5:55 AM EDT
Recruiting Not applicable Interventional

Endoscopic Sleeve Gastroplasty (ESG) for the Treatment of Obesity

NCT06339320
View directory record Official record
Conditions
Endoscopic Sleeve Gastroplasty, Obesity
Interventions
Endoscopic Sleeve Gastroplasty (ESG), Apollo OverStitch endoscopic suturing device
Procedure · Device
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
2
States / cities
Houston, Texas • Sugar Land, Texas
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced Oct 11, 2026, 5:55 AM EDT
Active, not recruiting Phase 2 Interventional

T-regulatory Cells in ALS

NCT04055623
View directory record Official record
Conditions
ALS (Amyotrophic Lateral Sclerosis)
Interventions
Monthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections, Monthly placebo infusions + 3 times per week placebo injections
Biological · Other
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Oct 11, 2026, 5:55 AM EDT
Enrolling by invitation Phase 4 Interventional

Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria

NCT05185505
View directory record Official record
Conditions
Hepatocellular Carcinoma, Hepatocellular Cancer
Interventions
Atezolizumab, Bevacizumab
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 11, 2026, 5:55 AM EDT
Not listed Not applicable Interventional

Physiological and Psychological Effects of Music Therapy in the Pregnant Woman and Fetus

NCT05893485
View directory record Official record
Conditions
Music Therapy, Preterm Premature Rupture of Membrane (PPROM)
Interventions
Music Therapy Intervention
Behavioral
Lead sponsor
Christina Chianis Reed
Other
Eligibility
18 Years to 64 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 11, 2026, 5:55 AM EDT
Active, not recruiting Phase 1 Interventional

iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma

NCT01953900
View directory record Official record
Conditions
Osteosarcoma, Neuroblastoma
Interventions
GD2 T cells, VZV vaccine, Fludarabine, Cyclophosphamide
Genetic · Biological · Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2034
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 11, 2026, 5:55 AM EDT